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Muscular dystrophy (MD) comprises a group of diseases characterized by progressive muscle weak-
ness that induces functional deterioration. Clinical management requires the use of a well-designed
scale to measure patients’ functional status. This study aimed to investigate the quality of the func-
tional scales used to assess patients with different types of MD. The Brooke scale and the Vignos
scale were used to grade arm and leg function, respectively. The Barthel Index was used to evaluate
the function of daily living activity. We performed tests to assess the acceptability of these scales.
The characteristics of the different types of MD are discussed. This was a multicenter study and
included patients diagnosed with Duchenne muscular dystrophy (DMD) (classified as severely
progressive MD), Becker muscular dystrophy (BMD), limb girdle muscular dystrophy (LGMD)
and facioscapulohumeral muscular dystrophy (FSHD). BMD, LGMD, and FSHD were classified
as slowly progressive MD. The results demonstrated that the Brooke scale was acceptable for grad-
ing arm function in DMD, but was unable to discriminate between differing levels of severity in
slowly progressive MD. The floor effect was large for all types of slowly progressive MD (range,
20.0–61.9), and was especially high for BMD. The floor effect was also large for BMD (23.8%) and
FSHD (50.0%) using the Vignos scale. Grades 6–8 of the Vignos scale were inapplicable because they
included items involving the use of long leg braces for walking or standing, and some patients
did not use long leg braces. In the Barthel Index, a ceiling effect was prominent for slowly progres-
sive MD (58.9%), while a floor effect existed for DMD (17.9%). Among the slowly progressive
MDs, FSHD patients had the best level of functioning; they had better leg function and their daily
living activities were less affected than patients with other forms of slowly progressive MD. The
results of this study demonstrate the acceptability of the different applications used for measuring
functional status in patients with different types of MD. Some of the limitations of these measures
as applied to MD should be carefully considered, especially in patients with slowly progressive MD.
We suggest that these applications be used in combination with other measures, or that a compli-
cated instrument capable of evaluating the various levels of functional status be used.
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Muscular dystrophy (MD) comprises a group of gen-
etic diseases that is marked by progressive muscle
weakness and atrophy. Various gene deficits cause
different clinical manifestations. Duchenne muscular
dystrophy (DMD) and Becker muscular dystrophy
(BMD) are both caused by defects in the Xp21 region
of the X chromosome [1]. The incidence of DMD is
about 1 in 3,500 male births; the symptoms present
during childhood and lead to rapid deterioration [2].
Other types of MD are less common, such as facioscap-
ulohumeral muscular dystrophy (FSHD) and limb
girdle muscular dystrophy (LGMD). The flawed gene
for FSHD is located on chromosome 5q35 and shows
autosomal dominant inheritance. The condition is 
characterized by weakness of the face, upper-arm and
shoulder girdle muscles [3]. LGMDs comprise a group
of genetic disorders mainly involving the pelvic and/or
shoulder girdle musculatures, and where transmission
is due to both autosomal recessive and dominant pat-
terns [4–6]. Many clinicians and therapists assess func-
tion as a means of determining changes [7,8]. The
suitability of the scales used for evaluating the func-
tional status is therefore an important issue in patients
with MD.
The Brooke and Vignos scales provide ordinal-level
data to assess the upper and lower extremity functions,
respectively [9,10]. These scales were initially designed
for DMD and many studies have used them to evalu-
ate functional status [11–13]. They are now also used
to evaluate the functional status of patients with neu-
romuscular diseases [14–16].
Use of the Brooke and Vignos scales to measure
function in other types of MD is still limited and,
although previous studies have included patients with
various types of MD, a detailed analysis of the accep-
tability of these scales for different types of MD is still
lacking. Acceptability is determined by examining
whether or not the score distributions adequately
represent the true distribution of functional status in
the sample [17,18]. Because different types of MD were
included within the same group in previous studies,
it was not possible to demonstrate the real functional
profile of the specific types of MD.
In addition to examining upper and lower extremity
functions, independent activities of daily living (ADL)
of patients are also important. The Barthel Index (BI) is
a simple, well-established reliable and valid scale,
and is one of the most widely used measurement
tools in rehabilitation centers. BI scores are also used
by the Bureau of Employment and Vocational
Training in Taiwan as criteria when hiring foreign
laborers as caregivers. Previous studies have used the
BI to assess the performance of ADL in DMD [19–21].
However, its acceptability for use in different types 
of MD has never been studied.
Assessing the acceptability of these scales for eva-
luating different types of MD could allow for precise
application of the scales. The aim of this study was
therefore to assess the acceptability of the scales for
evaluating the functional status of patients with 
various types of MD.
PATIENTS AND METHODS
Subjects
Patients with MD with a range of severities were
recruited from outpatient and inpatient units of the
neurological departments of hospitals participating
in a multicenter registration program for neuromus-
cular disease and in the development of an assess-
ment tool program for muscular dystrophy in Taiwan.
Four types of MD were included in this study: DMD,
BMD, FSHD, and LGMD. A definite diagnosis of MD
was confirmed by two neurologists on the basis of
clinical and genetic analyses, and electromyographic
and muscle biopsy criteria, according to the diagnostic
criteria for neuromuscular disorders from the European
Neuromuscular Research Group used at that time
[14,15,21–24]. Patients were excluded if they had any
other coexisting medical or psychiatric diseases. After
diagnosis, patients were followed-up at outpatient clin-
ics for at least 2 years to confirm the diagnosis. The
study was approved by the hospital’s institutional
review board, and written informed consent was
obtained from all participants.
Procedure
After diagnosis and follow-up, patients were evalu-
ated for functional status by four trained raters 
(2 physical therapists and 2 occupational therapists).
Most of the patients were evaluated in hospital, and
those who had difficulties in getting to the hospital
were evaluated by home visit. The Brooke scale was
applied for grading upper extremity function [9] 
and the Vignos scale was used for lower extremity
function [10]. The BI was used to evaluate ADL
ability [25].
Instruments
Brooke and Vignos scales
The grades on the Brooke scale range from 1 to 6; 
1 means that the patient is able to start with arms at
the sides and can abduct the arms in a full circle until
they touch above the head, while 6 means that they
are unable to raise their hands to their mouth and have
no useful function of the hands. On the Vignos scale,
the grade ranges from 1 to 10; 1 means that the patient
is able to walk and climb stairs without assistance,
while 10 means that the patient is bed-bound (Table 1).
Both the Brooke and Vignos scales are reliable with
high intraclass correlation values for DMD [26].
BI
The BI is a 10-item scale that measures functional
independence in the domains of personal care and
mobility. For each item, patients receive a score of 0 if
they are unable to carry out the activity, a maximum
score if able to perform the activity independently, and
an intermediate score if able to perform the activity
with assistance. Possible values are assigned in incre-
ments of 5. The totals can range from 0 to 100. The
reliability and validity of the BI administered by oral
interview, observation or telephone interview has been
well-established [27,28]. The total scores are broken
down into the following severity categories: 0–20 rep-
resents totally dependent, 21–61 severely dependent,
62–90 moderately dependent, 91–99 mildly depen-
dent, and 100 represents totally independent [29].
Data management and statistical analyses
To assess the acceptability of the instruments, missing
data, observed versus possible score ranges, floor and
ceiling effects, and skewedness were analyzed. The
floor and ceiling effects were the proportions of patients
with the minimum and maximum scores, respectively.
The skewedness measured the symmetry of the sam-
ple distribution [18,30].
Brooke scale, Vignos scale, and BI scores were
compared between severely progressive MD (DMD)
and slowly progressive MD (BMD, LGMD, FSHD)
using the Mann-Whitney U test. Brooke scale, Vignos
scale, and BI scores were compared among the slo-
wly progressive MDs (BMD, LGMD, FSHD) using the
nonparametric Kruskal-Wallis one-way analysis of
variance. The significance level was set at 0.05. All
statistical analyses were done with SPSS version 10.0
(SPSS Inc., Chicago, IL, USA) for Windows.
RESULTS
The study population comprised 179 patients from
Northern, Central, and Southern Taiwan. Eighty-four
patients (46.9%) were diagnosed with DMD and
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Table 1. Grading for Brooke and Vignos scales
Grade Functional description
Brook scale for upper extremities
1 Starting with arms at the sides, the patient can abduct the arms in a full circle until they touch
above the head
2 Can raise arms above head only by flexing the elbow (shortening the circumference of the 
movement) or using accessory muscles
3 Cannot raise hands above head, but can raise an 8-oz glass of water to the mouth
4 Can raise hands to the mouth, but cannot raise an 8-oz glass of water to the mouth
5 Cannot raise hands to the mouth, but can use hands to hold a pen or pick up pennies from the table
6 Cannot raise hands to the mouth and has no useful function of hands
Vignos scale for lower extremities
1 Walks and climbs stairs without assistance
2 Walks and climbs stair with aid of railing
3 Walks and climbs stairs slowly with aid of railing (over 25 seconds for 8 standard steps)
4 Walks unassisted and rises from chair but cannot climb stairs
5 Walks unassisted but cannot rise from chair or climb stairs
6 Walks only with assistance or walks independently with long leg braces
7 Walks in long leg braces but requires assistance for balance
8 Stands in long leg braces but unable to walk even with assistance
9 Is in a wheelchair
10 Is confined to a bed
were classified as having severely progressive MD.
Ninety-five patients (54.1%) were classified as having
slowly progressive MD, and included 21, 54 and 20
patients, respectively, with BMD, LGMD, and FSHD.
The demographic data for these patients with differ-
ent types of MD are shown in Table 2. All patients
with DMD or BMD, 60% of those with FSHD, and
59.3% of those with LGMD were male. The mean age
of patients with DMD was the lowest at about 12
years, while the mean age of patients with LGMD
was the highest at about 39 years. The mean disease
duration for the various types of MD ranged from 9.3
to 17.4 years.
The measures were easy to assess and it took about
5–10 minutes to complete the tests, and patients did
not feel uncomfortable. Less than 5% missing data is
considered to be acceptable [17], and no missing data
were found for any measures in this study.
The grade distributions for the Brooke and Vignos
scales are shown in Table 3. Most of the patients
(n = 135, 75.4%) were graded 1–3 for upper extremity
function using the Brooke scale, while using the Vignos
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Table 2. Characteristics of patients with different types of muscular dystrophy
Total sample DMD BMD FSHD LGMD
Number 179 (149/30) 84 (84/0) 21 (21/0) 20 (12/8) 54 (32/22)
(male/female)
Age (yr) 24.3 ± 16.5 (6–80) 12.4 ± 4.6 (6–26) 22.9 ± 9.8 (9–44) 35.5 ± 16.7 (13–80) 39.3 ± 15.6 (12–76)
Disease 13.1 ± 10.1 (2–70) 9.3 ± 4.8 (2–25) 13.4 ± 9.2 (2–32) 17.3 ± 14.5 (4–70) 17.4 ± 12.2 (2–64)
duration (yr)
Brooke 2.7 ± 1.7 (1–6) 3.2 ± 1.9 (1–6) 1.9 ± 1.5 (1–6) 2.3 ± 0.8 (1–3) 2.3 ± 1.3 (1–5)
scale (range)
Vignos 5.2 ± 3.4 (1–10) 7.1 ± 3.1 (1–10) 3.5 ± 2.7 (1–10) 2.2 ± 1.3 (1–5) 3.9 ± 2.7 (1–9)
scale (range)
Barthel 67.7 ± 35.6 (0–100) 44.3 ± 34.4 (0–100) 86.0 ± 29.1 (5–100) 97.8 ± 4.7 (85–100) 85.6 ± 20.2 (5–100)
Index (range)
DMD = Duchenne muscular dystrophy; BMD = Becker muscular dystrophy; FSHD = facioscapulohumeral muscular dystrophy;
LGMD = limb girdle muscular dystrophy.
Table 3. Distribution of Brooke and Vignos scales for different types of muscular dystrophy
Total sample DMD BMD FSHD LGMD
Brooke
1 65 (36.3%) 28 (33.3%) 13 (61.9%) 4 (20%) 20 (37%)
2 26 (14.5%) 6 (7.1%) 4 (19.0%) 6 (30%) 10 (18.5%)
3 44 (24.6%) 15 (17.9%) 1 (4.8%) 10 (50%) 18 (33.3%)
4 8 (4.4 %) 8 (9.5%) 0 0 0
5 18 (10.1%) 10 (11.9%) 2 (9.5%) 0 6 (11.1%)
6 18 (10.1%) 17 (20.2%) 1 (4.8%) 0 0
Vignos
1 27 (15.1%) 4 (4.8%) 5 (23.8%) 10 (50%) 8 (14.8%)
2 26 (14.5%) 9 (10.7%) 5 (23.8%) 2 (10%) 10 (18.5%)
3 32 (17.9%) 8 (9.5%) 4 (19.0%) 4 (20%) 16 (29.6%)
4 13 (7.3%) 2 (2.4%) 2 (9.5%) 3 (15%) 6 (11.1%)
5 9 (5.0%) 3 (3.6%) 2 (9.5%) 1 (5%) 3 (5.6%)
6 4 (2.2%) 3 (3.6%) 0 0 1 (1.9%)
7 0 0 0 0 0
8 1 (0.6%) 1 (1.2%) 0 0 0
9 51 (28.5%) 39 (46.4%) 2 (9.5%) 0 10 (18.5%)
10 16 (8.9%) 15 (17.9%) 1 (4.8%) 0 0
Total number 179 84 21 20 54
DMD = Duchenne muscular dystrophy; BMD = Becker muscular dystrophy; FSHD = facioscapulohumeral muscular dystrophy;
LGMD = limb girdle muscular dystrophy.
scale for lower extremity function, 51 patients (28.5%)
were grade 9 and confined to wheelchairs. Only five
(2.8%) patients were graded 6–8 and they used long
leg braces for walking or standing.
The acceptabilities of the Brooke and Vignos
scales are shown in Table 4. The mean Brooke scores
were 3.2 (DMD), 1.9 (BMD), 2.3 (FSHD) and 2.3
(LGMD), and the mean Vignos scores were 7.1
(DMD), 3.5 (BMD), 2.2 (FSHD) and 3.9 (LGMD). The
floor effect in the Brooke scale was large for all types
of MD, ranging from 20.0 to 61.9, and was especially
high in BMD patients. The ceiling effect was slightly
increased (20.2%) for patients with DMD. The floor
effect in the Vignos scale was large for patients with
BMD (23.8%) and FSHD (50.0%), while for patients
with DMD, the ceiling effect was also slightly in-
creased (17.9%). The acceptable skewedness criterion
was −1 to + 1 [30]. The skewedness of the Brooke scale
for all types of MD was 0.7, ranging from −0.6 to 1.8
for each type of MD, and that of the Vignos scale for
all types of MD was 0.2, ranging from −0.8 to 1.4 for
each type of MD.
The acceptability of the BI and the indicated depen-
dence severity are shown in Table 5. Most patients
with DMD were totally (n = 23, 27.4%) or severely
(n = 35, 41.7%) dependent, while most patients with
BMD, FSHD, and LGMD were totally independent
(59%). When applied to the summary scores, floor and
ceiling effects > 15% were considered to be significant
[31]. The ceiling effect was 34.1% based on all types
of MD, and 58.9% for slowly progressive MD (range,
48.1–80.0%). The floor effect still existed for patients
with DMD (17.9%) but the ceiling effect was only 6.0%.
Skewedness for all types of MD was −0.7, ranging
from −2.3 to 0.3 for each type of MD.
The mean scores on the Brooke scale (3.2 ± 1.9),
Vignos scale (7.1 ± 3.1), and BI (44.5 ± 34.4) for patients
with DMD (severely progressive MD) were signifi-
cantly different from those with slowly progressive
MD (Brooke scale, 2.2 ± 1.3; Vignos scale, 3.4 ± 2.6; BI,
88.2 ± 20.1) by the Mann-Whitney U test (z = −3.2,
p = 0.001; z = −6.8, p < 0.001; and z = −8.5, p < 0.001, res-
pectively; Tables 4 and 5). There were no significant
differences in upper extremity function among the
different types of slowly progressive MD (χ2 = 4.8,
p = 0.09), but lower extremity function and ADL were
significantly different (χ2 = 7.4, p = 0.03; and χ2 = 7.5,
p = 0.02, respectively).
DISCUSSION
This study included patients with various types of
MD and evaluated their functional status using the
Brooke and Vignos scales and the BI. These scales
were quick and easy to apply as means of measuring
the functional status of patients with MD, and no miss-
ing data were found. In patients with slowly progres-
sive MD, leg function was seldom graded 6, 7 or 8
using the Vignos scale, and arm function was seldom
Function in muscular dystrophy
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Table 4. Acceptability of Brooke and Vignos scales for different types of muscular dystrophy
Mean ± SD Observed score (range) Skewedness Floor effect (%) Ceiling effect (%)
Brooke scale
Total sample 2.7 ± 1.7 1–6 0.7 36.3 10.1
DMD 3.2 ± 1.9 1–6 0.2 33.3 20.2
Slowly progressive MD 2.2 ± 1.3* 1–6 1.0 38.9 1.1
BMD 1.9 ± 1.5 1–6 1.8 61.9 4.8
FSHD 2.3 ± 0.8 1–3 −0.6 20.0 0
LGMD 2.3 ± 1.3 1–5 −0.2 37 0
Vignos scale
Total sample 5.2 ± 3.4 1–10 0.2 15.1 8.9
DMD 7.1 ± 3.1 1–10 −0.8 4.8 17.9
Slowly progressive MD 3.4 ± 2.6† 1–10 1.3 24.2 1.1
BMD 3.5 ± 2.7 1–10 1.4 23.8 4.8
FSHD 2.2 ± 1.3 1–5 0.7 50.0 0
LGMD 3.9 ± 2.7 1–9 1.1 14.8 0
*p = 0.001, †p < 0.001 (slowly progressive MD compared with DMD by Mann-Whitney U test). DMD = Duchenne muscular dystrophy;
BMD = Becker muscular dystrophy; FSHD = facioscapulohumeral muscular dystrophy; LGMD = limb girdle muscular dystrophy.
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graded 4, 5 or 6 using the Brooke scale. The BI
showed a prominent ceiling effect in slowly progres-
sive MD, and a floor effect in patients with DMD.
The Brooke scale was the best available measure
for grading arm function in patients with severely
progressive MD (DMD), but was not appropriate for
those with slowly progressive MD (BMD, LGMD,
FSHD). Most patients with slowly progressive MD
were graded 1–3, which indicated that grades 4–6
were too simple for most of these cases. Integrated,
more functional assessment items, may be needed to
discriminate arm function, especially high level func-
tional activity, in slowly progressive MD.
Vignos grades 6–8 were inapplicable in some
cases because these grades covered the ability to walk
with or without assistance and standing with a long
leg brace. This could have been due to cultural differ-
ences in the use of long leg braces, but other studies
also found that only a few patients were graded bet-
ween 6 and 8, and they felt uncomfortable walking
with a long leg brace [11,32]. When a patient is unable
to walk independently and does not use a long leg
brace for walking or standing, the leg function will
change from grade 5 to grade 9. Although we strongly
agree that using a long leg brace is an important trea-
tment option for patients with MD, possible problems
in assessing the leg function of grades 6–8 need careful
consideration.
The acceptability of the BI differed between severely
and slowly progressive MDs. A prominent ceiling
effect was found in slowly progressive MD, whereas
a floor effect was found in severely progressive MD.
Ceiling effects for the BI have been found in many
studies [33–36]. The BI may have limited ability to
discriminate between outcomes in individuals with
slowly progressive MD. Of the different types of
slowly progressive MD, FSHD was associated with
the best leg function and ADL was less affected than
in the other types of MD.
A possible reason for the existence of the floor
effect seen in DMD may be that those patients were
very weak and lacked even basic mobility, such as
the ability to roll or to move from a supine to a sitting
position during the end stage of the disease. However,
the BI is not designed for lower level mobility items.
The use of some basic mobility items for patients with
severely progressive MD and some higher level func-
tional items for those with slowly progressive MD
may therefore be needed.
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A comprehensive scale able to evaluate the varied
clinical problems is an important tool. The Muscular
Dystrophy Functional Rating Scale was designed to
fit the gap in assessing patients with various types of
MD, and the scale has been demonstrated to have
good reliability and validity [7,37].
Several limitations of our study are worth noting.
One limitation was the lack of a reliability and val-
idity study. Reliability and validity are important for
determining the stability and confirming that the
content of a scale represents the concept that it is
intended to measure. The second limitation was 
that our sample only included patients with DMD,
BMD, FSHD, and LGMD; other types of MD may
present with different clinical profiles. The third limi-
tation was that the subtypes of LGMD were not 
identified in our study. LGMDs are a heterogeneous
group of inherited diseases and 19 different subtypes
have been reported [38]. Subtypes of LGMD show
clinical variability and difficulties in classification
arise due to common sporadic cases [39,40]. Ethnic
clusters and specific geographic origins are com-
monly found for certain subtypes of LGMD, such 
as LGMD 2A, which is the most prevalent form 
in Japan, Turkey, and Brazil [41–43]. Future studies 
in Taiwan are needed to investigate the types of
genetic deficiencies and to explore the influence of
functional performance in patients with muscular
dystrophy.
This study investigated the Brooke and Vignos
scales, and the BI as instruments for measuring the
functional status of patients with different types of
MD. This study included a large sample of patients
with MD and demonstrates that the Brooke scale and
BI are too simple to identify functional changes in
patients with slowly progressive MD. For patients
with DMD, the addition of basic mobility items may
be needed to evaluate their function, due to the floor
effect of the BI.
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不同類型肌肉失養症功能狀態之評估
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肌肉失養症 (muscular dystrophy) 是一群漸進性肌肉無力疾病，並造成功能持續退
步。使用設計良好的評估表來正確評估功能狀態，為治療重要的基礎。本研究目的為
檢測評估功能工具，使用於不同類型肌肉失養症功能狀態其合適情形。以 Brooke 和 
Vignos 評估表分別評估上肢及下肢功能等級，以巴歇爾指數 (Barthel index) 評估日
常活動的功能。統計檢測各種評估工具對不同類型肌肉失養症的接受度 
(acceptability)，並討論不同類型的表現。病患來自台灣多個醫療院所，共有 179 
位，46.9% 為裘馨型肌肉失養症 (Duchenne muscular dystrophy)，屬於嚴重進展
的肌肉失養症；其餘 53.1% 為貝克型肌肉失養症 (Becker muscular dystrophy)、
肢帶型肌肉失養症 (limb girdle muscular dystrophy) 與顏肩肱型肌肉失養症 
(fascioscapulohumeral muscular dystrophy)，屬於緩慢進展的肌肉失養症。結果
顯示 Brooke 評估表適用於裘馨型肌肉失養症，但不易分辨緩慢進展的肌肉失養症，
其地板效應 (floor effect) 都較大 (範圍為 20.0% 至 61.9%)，尤其是貝克型肌肉失
養症。Vignos 評估表方面，同樣的貝克型 (23.8%) 與顏肩肱型 (50.0%) 肌肉失養症
有較大的地板效應，除此以外其評估等級 6 到 8，有一些病患並不適用，因這些等級
為使用長腿支架 (long leg brace) 來行走或站立，而他們並沒有使用。巴歇爾指數天
花板效應 (ceiling effect) 在緩慢進展的肌肉失養症病患非常顯著，而地板效應 (floor 
effect) 出現在裘馨型肌肉失養症病患。緩慢進展的肌肉失養症中以顏肩肱型肌肉失養
症病患功能最佳，有比較好的下肢功能，日常生活功能也較好。本研究提供使用功能
評估表於不同類型之肌肉失養症病患時之接受度，這些功能評估表出現的一些限制，
在臨床上使用時應特別留意，尤其是使用於緩慢進展的肌肉失養症，建議使用時可考
慮合併其他評估或使用題型結構較完整的評估量表。
關鍵詞：巴歇爾指數，功能狀態，肌肉失養症
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